EFFECT OF BISPHOSPHONATES ON THE ALVEOLAR BONE OF RATS WITH GLUCOCORTICOIDS INDUCED OSTEOPOROSIS

Document Type : Original Article

Authors

1 Assistant Lecturer of Oral biology, Faculty of Dentistry, Alexandria University.

2 Professor of Oral Biology, Faculty of Dentistry, Alexandria University.

3 Lecturer of Oral Biology, Faculty of Dentistry, Alexandria University

Abstract

INTRODUCTION: Bone is a unique tissue that undergoes frequent remodeling. An imbalance between bone formation and resorption results in osteoporosis. Glucocorticoids (GCs) are widely used clinically as anti-inflammatory and immunomodulatory. However, their prolonged use may induce osteoporosis. Currently, evidences revealed that also the alveolar processes are subject to osteoporosis. Bisphosphonates, such as Alendronate, Risedronate and Zoledronate, are recommended by several international guidelines as the first-line therapy for the prevention and treatment of generalized glucocorticoids induced osteoporosis (GIOP). OBJECTIVES: To evaluate the effect of bisphosphonates (Risedronate) on the alveolar bone of rats with glucocorticoids induced osteoporosis. MATERIALS AND METHODS: Thirty female albino rats were divided into 3 equal groups (10 rats each) as follows: Group I: control group. Group II: glucocorticoids group (Dexamethasone 0.6mg/kg twice/week subcutaneously). Group III: Risedronate treated group; rats were given Dexamethasone (0.6mg/kg twice/week subcutaneously) and Risedronate (1mg/kg/day orally). After 12 weeks, rats were euthanized, and the mandibular alveolar bone was evaluated histologically by light microscope and ultra-structurally by scanning electron microscopy and energy dispersive X-ray (EDX) microanalysis. RESULTS: Group II showed deterioration of the alveolar bone in comparison to the control group I. The alveolar bone structure in Group III rats, treated by bisphosphonates (Risedronate), showed remarkable improvement both histologically and ultrastructurally in comparison to group II. Moreover, EDX analysis revealed a significant decrease of calcium levels in group II in comparison to group I. However, in group III calcium levels were restored to normal levels comparable to the control group I. CONCLUSIONS: Glucocorticoids intake induces loss of the alveolar bone; which, could be counterbalanced by bisphosphonates.

Keywords

Main Subjects

References

  1. Jensen PR, Andersen TL, Hauge E-M, Bollerslev J, Delaissé J-M. A joined role of canopy and reversal cells in bone remodeling—lessons from glucocorticoid-induced osteoporosis. Bone. 2015;73:16-23.
  2. Oheim R, Schinke T, Amling M, Pogoda P. Can we induce osteoporosis in animals comparable to the human situation? Injury. 2016;47:S3-S9.
  3. Zhang Z, Ren H, Shen G, Qiu T, Liang D, Yang Z, et al. Animal models for glucocorticoid-induced postmenopausal osteoporosis: An updated review. Biomed Pharmacother. 2016;84:438-46.
  4. Whittier X, Saag KG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2016;42:177-89.
  5. Soriano R, Herrera S, Nogués X, Diez-Perez A. Current and future treatments of secondary osteoporosis. Best Pract Res Clin Endocrinol Metab. 2014;28:885-94.
  6. Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD open. 2015;1:e000014.
  7. Zhou C, Zhang S, Wang H, Dong L, Zhou G, Song H, et al. Anti-osteoporotic activity of the ethanol extracts of eucommia ulmoides in glucocorticoid-induced osteoporosis male rats through the activation of androgen receptor signaling. Int J Clin Exp Med. 2016;9:2148-56.
  8. Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 2013;1:59-70.
  9. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol. 2017;76:1-9.
  10. Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine. 2014;81:493-501.
  11. Komori T. Glucocorticoid signaling and bone biology. Horm Metab Res. 2016;48:755-63.
  12. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6:82-8.
  13. Bartl R. Corticosteroid-Induced Osteoporosis. Bone Disorders: Springer; 2017. p. 431-4.
  14. Avery JK, Chiego DJ. Essentials of Oral Histology and Embryology: A Clinical Approach: Mosby Elsevier; 2006.
  15. Lucinda L, Vieira B, Oliveira T, Sa R, Peters V, Reis J, et al. Evidences of osteoporosis improvement in Wistar rats treated with Ginkgo biloba extract: a histomorphometric study of mandible and femur. Fitoterapia. 2010;81:982-7.
  16. Bouvard B, Gallois Y, Legrand E, Audran M, Chappard D. Glucocorticoids reduce alveolar and trabecular bone in mice. Joint Bone Spine. 2013;80:77-81.
  17. Kozai Y, Kawamata R, Sakurai T, Kanno M, Kashima I. Influence of prednisolone-induced osteoporosis on bone mass and bone quality of the mandible in rats. Dentomaxillofac Radiol. 2009;38:34-41.
  18. Sousa LH, Moura EV, Queiroz AL, Val D, Chaves H, Lisboa M, et al. Effects of glucocorticoid-induced osteoporosis on bone tissue of rats with experimental periodontitis. Arch Oral Biol. 2017;77:55-61.
  19. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐ Induced Osteoporosis. Arthritis Care Res (Hoboken). 2017.
  20. Ren H, Liang D, Jiang X, Tang J, Cui J, Wei Q, et al. Variance of spinal osteoporosis induced by dexamethasone and methylprednisolone and its associated mechanism. Steroids. 2015;102:65-75.
  21. Shata A, Firgany AE-DL, Abdel-Hamid AA. Ameliorating effect of combination of simvastatin and Risedronate on glucocorticoid induced osteoporosis model in rats. Afr J Pharm Pharmacol. 2015;9:701-10.
  22. Fujita Y, Watanabe K, Uchikanbori S, Maki K. Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats. Am J Orthod Dentofacial Orthop. 2011;139:e267-e77.
  23. Johnson PD, Besselsen DG. Practical aspects of experimental design in animal research. ILAR journal. 2002;43:202-6.
  24. Kumar G. Preparation of Specimens for Histologic Study. In: Kumar G, editor. Orban's Oral Histology & Embryology. 13th ed. India: Elsevier Health Sciences; 2014. p. 410-6.
  25. Feldman AT, Wolfe D. Tissue processing and hematoxylin and eosin staining. In: Day C, editor. Histopathology: Methods and Protocols 1180. New York: Humana Press; 2014. p. 31-43.
  26. Murtey MD, Ramasamy P. Sample Preparations for Scanning Electron Microscopy–Life Sciences. Modern Electron Microscopy in Physical and Life Sciences: InTech; 2016.
  27. Helen EG, Winston WW. Methods for Transmission and Scanning Electron Microscopy of Bone and Cartilage. In: An YH, Martin KL, editors. Handbook of Histology Methods for Bone and Cartilage: Humana Press; 2003. p. 499-501.
  28. Goldstein J, Newbury DE, Echlin P, Joy DC, Romig Jr AD, Lyman CE, et al. Scanning electron microscopy and X-ray microanalysis: a text for biologists, materials scientists, and geologists: Springer Science & Business Media; 2012.
  29. Komori T. Animal models for osteoporosis. Eur J Pharmacol. 2015;759:287-94.
  30. Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA. The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008;58:424-30.
  31. Wood CL, Soucek O, Wong SC, Zaman F, Farquharson C, Savendahl L, et al. Animal models to explore the effects of glucocorticoids on skeletal growth and structure. J Endocrinol. 2018;236:R69-R91.
  32. Liang D, Ren H, Qiu T, Shen G, Xie B, Wei Q, et al. Extracts from plastrum testudinis reverse glucocorticoid-induced spinal osteoporosis of rats via targeting osteoblastic and osteoclastic markers. Biomed Pharmacother. 2016;82:151- 60.
  33. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-82.
  34. Hozayen WG, El-Desouky MA, Soliman HA, Ahmed RR, Khaliefa AK. Antiosteoporotic effect of Petroselinum crispum, Ocimum basilicum and Cichorium intybus L. in glucocorticoid-induced osteoporosis in rats. BMC Complement Altern Med. 2016;16:165.
  35. Cawthorn WP, Scheller EL, Parlee SD, Pham HA, Learman BS, Redshaw CM, et al. Expansion of bone marrow adipose tissue during caloric restriction is associated with increased circulating glucocorticoids and not with hypoleptinemia. Endocrinology. 2015;157:508-21.
  36. Song M, Alshaikh A, Kim T, Kim S, Dang M, Mehrazarin S, et al. Preexisting periapical inflammatory condition exacerbates tooth extraction–induced bisphosphonaterelated osteonecrosis of the jaw lesions in mice. J Endod. 2016;42:1641-6.
  37. Misof BM, Blouin S, Lueger S, Paschalis E, Recker R, Phipps R, et al. Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients. J Musculoskelet Neuronal Interact. 2017;17:183.
Alexandria Dental Journal
Volume 44, Issue 3
December 2019
Pages 65-70

Files

Share

How to cite

Statistics